DE69637332D1 - Kombinierung von PDGF, KGF, IGF und IGFBP für Wundheilung - Google Patents

Kombinierung von PDGF, KGF, IGF und IGFBP für Wundheilung

Info

Publication number
DE69637332D1
DE69637332D1 DE69637332T DE69637332T DE69637332D1 DE 69637332 D1 DE69637332 D1 DE 69637332D1 DE 69637332 T DE69637332 T DE 69637332T DE 69637332 T DE69637332 T DE 69637332T DE 69637332 D1 DE69637332 D1 DE 69637332D1
Authority
DE
Germany
Prior art keywords
pdgf
kgf
igf
combination
igfbp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69637332T
Other languages
English (en)
Other versions
DE69637332T2 (de
Inventor
Lewis T Williams
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Novartis Vaccines and Diagnostics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Vaccines and Diagnostics Inc filed Critical Novartis Vaccines and Diagnostics Inc
Publication of DE69637332D1 publication Critical patent/DE69637332D1/de
Application granted granted Critical
Publication of DE69637332T2 publication Critical patent/DE69637332T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/49—Platelet-derived growth factor [PDGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1754—Insulin-like growth factor binding proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors (Somatomedins), e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7015—Drug-containing film-forming compositions, e.g. spray-on
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
    • A61L26/0028—Polypeptides; Proteins; Degradation products thereof
    • A61L26/0047—Specific proteins or polypeptides not covered by groups A61L26/0033 - A61L26/0042
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Materials Engineering (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE69637332T 1995-10-11 1996-09-27 Kombinierung von PDGF, KGF, IGF und IGFBP für Wundheilung Expired - Lifetime DE69637332T2 (de)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US507595P 1995-10-11 1995-10-11
US5075P 1995-10-11
US2154096P 1996-07-11 1996-07-11
US21540P 1996-07-11
US71974296A 1996-09-25 1996-09-25
US719742P 1996-09-25

Publications (2)

Publication Number Publication Date
DE69637332D1 true DE69637332D1 (de) 2008-01-03
DE69637332T2 DE69637332T2 (de) 2008-10-09

Family

ID=27357798

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69633194T Expired - Lifetime DE69633194T2 (de) 1995-10-11 1996-09-27 Kombination pdgf, kgf, igf und igfbp zur wundheilung
DE69637332T Expired - Lifetime DE69637332T2 (de) 1995-10-11 1996-09-27 Kombinierung von PDGF, KGF, IGF und IGFBP für Wundheilung

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE69633194T Expired - Lifetime DE69633194T2 (de) 1995-10-11 1996-09-27 Kombination pdgf, kgf, igf und igfbp zur wundheilung

Country Status (11)

Country Link
US (2) US6903078B1 (de)
EP (2) EP1486565B1 (de)
JP (2) JPH11513405A (de)
AT (1) ATE274056T1 (de)
AU (1) AU7248896A (de)
DE (2) DE69633194T2 (de)
DK (1) DK1486565T3 (de)
ES (2) ES2293137T3 (de)
HK (1) HK1067382A1 (de)
PT (2) PT1486565E (de)
WO (1) WO1997013857A1 (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2293137T3 (es) 1995-10-11 2008-03-16 Novartis Vaccines And Diagnostics, Inc. Combinacion de pdgf, kgf,igf e igfbp para curacion de heridas.
CA2268741C (en) * 1996-10-15 2007-04-24 Amgen Inc. Uses of keratinocyte growth factor-2
EP1452205B1 (de) * 1996-10-15 2007-11-28 Amgen Inc. Verwendung von keratinocyte growth factor-2
US6743422B1 (en) 1996-10-15 2004-06-01 Amgen, Inc. Keratinocyte growth factor-2 products
AU6691098A (en) 1997-03-07 1998-09-22 Wistar Institute Of Anatomy & Biology, The Method and compositions for healing tissue defects and inducing hypervascularityin mammalian tissue
WO2003018752A2 (en) 2001-08-23 2003-03-06 The Wistar Institute Of Anatomy And Biology An organotypic intestinal culture and methods of use thereof
US7202066B2 (en) * 2002-01-29 2007-04-10 Carrington Laboratories, Inc. Combination of a growth factor and a protease enzyme
JP2006503545A (ja) * 2002-02-14 2006-02-02 ラター， ウィリアム ジェイ． 処置される宿主における切断についてのキメラ分子
US20050224082A1 (en) * 2004-04-05 2005-10-13 Johnson Arthur A Method for forming occlusive barrier over ear canal and kit for providing same
US7473678B2 (en) * 2004-10-14 2009-01-06 Biomimetic Therapeutics, Inc. Platelet-derived growth factor compositions and methods of use thereof
US20070004036A1 (en) * 2005-07-01 2007-01-04 Rodolfo Faudoa Methods and compositions for keratinocyte culture
US20070128685A1 (en) * 2005-07-01 2007-06-07 Rodolfo Faudoa Methods and compositions for cell culture
US20070003541A1 (en) * 2005-07-01 2007-01-04 Rodolfo Faudoa Methods and compositions for therapeutics
CA2630077C (en) 2005-11-17 2014-07-15 Biomimetic Therapeutics, Inc. Maxillofacial bone augmentation using rhpdgf-bb and a biocompatible matrix
WO2007092622A2 (en) 2006-02-09 2007-08-16 Biomimetic Therapeutics, Inc. Compositions and methods for treating bone
GB0611405D0 (en) * 2006-06-09 2006-07-19 Univ Belfast FKBP-L: A novel inhibitor of angiogenesis
ES2664229T3 (es) 2006-06-30 2018-04-18 Biomimetic Therapeutics, Llc Composiciones y métodos de biomatriz-PDGF para el tratamiento de lesiones del manguito rotador
US9161967B2 (en) 2006-06-30 2015-10-20 Biomimetic Therapeutics, Llc Compositions and methods for treating the vertebral column
WO2008005533A2 (en) * 2006-07-06 2008-01-10 Aaron Thomas Tabor Compositions and methods for genetic modification of cells having cosmetic function to enhance cosmetic appearance
EP2086598B1 (de) 2006-11-03 2015-05-27 BioMimetic Therapeutics, LLC Zusammensetzungen und verfahren für behandlungen von arthrodese
CN101965193A (zh) 2006-11-15 2011-02-02 科达治疗公司 用于伤口愈合的改进方法和组合物
US20080195476A1 (en) * 2007-02-09 2008-08-14 Marchese Michael A Abandonment remarketing system
US20110217313A1 (en) * 2007-12-21 2011-09-08 Becker David L Treatment of orthopedic conditions
AU2008343843A1 (en) * 2007-12-21 2009-07-09 Coda Therapeutics, Inc. Improved medical devices
US20110130710A1 (en) * 2007-12-21 2011-06-02 David Lawrence Becker Treatment of abnormal or excessive scars
ES2422259T3 (es) * 2008-02-07 2013-09-10 Biomimetic Therapeutics Inc Composiciones para la osteogénesis por distracción
KR101021197B1 (ko) * 2008-04-11 2011-03-11 (주)케어젠 성장인자―미미킹 펩타이드 및 그의 용도
NZ591338A (en) 2008-09-09 2013-02-22 Biomimetic Therapeutics Inc Platelet-derived growth factor compositions and methods for the treatment of tendon and ligament injuries
US20100247651A1 (en) * 2009-03-05 2010-09-30 Biomimetic Therapeutics, Inc. Platelet-derived growth factor compositions and methods for the treatment of osteochondral defects
BR112012000865A2 (pt) 2009-07-17 2019-09-24 T Tabor Aaron "composição e método para a modificação genética cosmética de células substancialmente intactas"
WO2011103598A1 (en) 2010-02-22 2011-08-25 Biomimetic Therapeutics, Inc. Platelet-derived growth factor compositions and methods for the treatment of tendinopathies
US10279007B2 (en) 2010-11-15 2019-05-07 Oxygenetix Institute, Inc. Topical treatment method for healing wounds, disinfecting, covering and concealing the wound until healing occurs
WO2015063613A2 (en) 2013-11-01 2015-05-07 Spherium Biomed S.L. Inclusion bodies for transdermal delivery of therapeutic and cosmetic agents
CA2958879A1 (en) 2014-08-22 2016-02-25 Auckland Uniservices Limited Channel modulators
JP6871855B2 (ja) 2014-10-14 2021-05-19 サムエル リンチ， 創傷を処置するための組成物
CN110590930B (zh) * 2018-06-13 2023-03-31 四川好医生攀西药业有限责任公司 美洲大蠊生长因子pdgf在制备损伤修复药物中的应用

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0561137B1 (de) 1983-04-25 2002-07-03 Chiron Corporation Hybrid-DNS-Synthesis von reifen insulinähnlichen Wachstumsfaktoren
US4801542A (en) * 1984-10-12 1989-01-31 Zymogenetics, Inc. Expression of biologically active PDGF analogs in eucaryotic cells
US4766073A (en) * 1985-02-25 1988-08-23 Zymogenetics Inc. Expression of biologically active PDGF analogs in eucaryotic cells
US5187263A (en) 1984-10-12 1993-02-16 Zymogenetics, Inc. Expression of biologically active PDGE analogs in eucaryotic cells
DE3751632T2 (de) * 1986-08-13 1996-06-13 Zymogenetics Inc Expression von biologisch-aktiven PDGF-Analogen in eukaryotischen Zellen
JPH01500199A (ja) 1986-11-14 1989-01-26 インスティチュート・オブ・モレキュラー・バイオロジー・インコーポレーテッド 創傷の治癒および骨の再生
US5019559A (en) 1986-11-14 1991-05-28 President And Fellows Of Harvard College Wound healing using PDGF and IGF-II
CA1322714C (en) 1986-11-14 1993-10-05 Harry N. Antoniades Wound healing and bone regeneration
US4885163A (en) 1987-02-24 1989-12-05 Eli Lilly And Company Topical use of IGF-II for wound healing
US5422120A (en) * 1988-05-30 1995-06-06 Depotech Corporation Heterovesicular liposomes
EP0555205B1 (de) 1989-01-31 2000-11-29 RUBIN, Jeffrey S Dns kodierend für einen für epithelzellen spezifischen wachstumsfaktor
US5035887A (en) 1989-09-07 1991-07-30 Institute Of Moelcular Biology, Inc. Wound healing composition of IL-1 and PDGF or IGF-1
US5149792A (en) * 1989-12-19 1992-09-22 Amgen Inc. Platelet-derived growth factor B chain analogs
JPH04224522A (ja) * 1990-04-27 1992-08-13 Merck & Co Inc 繊維芽細胞増殖因子含有組成物による禿頭症の治療又は予防方法
DK0547064T3 (da) * 1990-07-23 1995-03-20 Zymogenetics Inc Proteaseresistent PDGF og anvendelsesfremgangsmåde
CA2090702A1 (en) 1990-08-28 1992-03-01 Michael C. Kiefer Insulin-like growth factor binding protein igfbp-5
US5212074A (en) 1990-08-28 1993-05-18 Chiron Corporation Genetic material encoding new insulin-like growth factor binding protein igfbp-6
JPH06503947A (ja) 1990-08-28 1994-05-12 カイロン　コーポレイション Ｉｇｆｂｐ―５をコードする遺伝物質
DE69233155T2 (de) 1991-01-08 2004-06-03 Chiron Corp. (N.D.Ges.D. Staates Delaware), Emeryville Insulinartigen wachstumsfaktor bindendes protein
JPH05506673A (ja) * 1991-02-22 1993-09-30 アムジエン・インコーポレーテツド 迅速な創傷の治癒を促進するためのｇｍ―ｃｓｆ及びｇ―ｃｓｆの使用
WO1992018154A1 (en) 1991-04-19 1992-10-29 Boehringer Mannheim Gmbh Human bone derived insulin like growth factor binding protein
HUT67319A (en) 1991-08-30 1995-03-28 Life Medical Sciences Inc Compositions for treating wounds
IL105529A0 (en) * 1992-05-01 1993-08-18 Amgen Inc Collagen-containing sponges as drug delivery for proteins
EP0661990B1 (de) * 1992-08-26 2002-04-10 Celtrix Pharmaceuticals, Inc. Verfahren zur systemischen behandlung katabolischer zustände und systemischer gewebeschädigung
US5407913A (en) 1992-12-03 1995-04-18 Celtrix Pharmaceuticals, Inc. Method and composition for systemic treatment of tissue injury
EP0686040A1 (de) * 1993-01-29 1995-12-13 Amgen Boulder Inc. Wunden heilende zusammensetzumg
SK281674B6 (sk) * 1993-03-26 2001-06-11 Amgen Inc. Farmaceutická kompozícia na stimuláciu hepatocytov, pneumocytov typu ii, pohárikovitých buniek produkujúcich mucín a iných epitelových buniek
US5750365A (en) * 1993-05-28 1998-05-12 The Ohio State University Research Foundation Isolated nucleic acid encoding a newt acidic fibroblast growth factor (AFGF)
NZ266622A (en) 1993-06-29 1997-10-24 Chiron Corp Keratinocyte growth factor fragment (kgf) with at least a 2-fold increase in mitogenic activity compared to a full length kgf; dna molecules, expression vectors, host cells, and conjugates
US5624893A (en) 1993-10-14 1997-04-29 Alcon Laboratories, Inc. Pharmaceutical compositions and methods of treatment of the cornea following laser irradiation
US5962427A (en) * 1994-02-18 1999-10-05 The Regent Of The University Of Michigan In vivo gene transfer methods for wound healing
ES2293137T3 (es) 1995-10-11 2008-03-16 Novartis Vaccines And Diagnostics, Inc. Combinacion de pdgf, kgf,igf e igfbp para curacion de heridas.

Also Published As

Publication number Publication date
HK1067382A1 (en) 2005-04-08
ATE274056T1 (de) 2004-09-15
DK1486565T3 (da) 2008-03-10
PT871730E (pt) 2004-11-30
US20050250695A1 (en) 2005-11-10
US6903078B1 (en) 2005-06-07
EP1486565B1 (de) 2007-11-21
AU7248896A (en) 1997-04-30
WO1997013857A1 (en) 1997-04-17
DE69633194D1 (de) 2004-10-21
DE69633194T2 (de) 2005-09-08
EP0871730B1 (de) 2004-08-18
PT1486565E (pt) 2008-02-28
EP1486565A1 (de) 2004-12-15
ES2224178T3 (es) 2005-03-01
EP0871730A1 (de) 1998-10-21
JP2007182461A (ja) 2007-07-19
JPH11513405A (ja) 1999-11-16
DE69637332T2 (de) 2008-10-09
ES2293137T3 (es) 2008-03-16

Similar Documents

Publication Publication Date Title
DE69637332D1 (de) Kombinierung von PDGF, KGF, IGF und IGFBP für Wundheilung
DE69536017D1 (de) Methoden und zusammensetzungen für die behandlung von glomerulonephritis
ID21924A (id) Olanzapin dihidrat d
DK1489082T3 (da) Mellemprodukter
ATE369131T1 (de) Verwendung von agonisten des zentralen cannabinoid-rezeptors cb1
ATE416755T1 (de) Verfahren und zusammensetzung für die pulmonale darreichung von insulin
DK151687A (da) Aprotinin-homologe fremstillet ud fra en rekombinant vaert, fremgangsmaade, ekspressionsvektor og rekombinant vaert derfor og farmaceutisk anvendelse deraf
DK0871473T3 (da) Anvendelse af IL-10 til sårheling med reduceret ardannelse
ATE215379T1 (de) Antifungaleverfahren und mitteln
DE69532085D1 (de) Behälter für die mikrowellenbehandlung von chirurgischen instrumente mit lichtbogenverhütung
DE69609256T2 (de) Sicheres aktualisierungsverfahren für eeprom
DE4397203T1 (de) Helligkeitssteuersystem für eine zahnärztliche Handstückbeleuchtung
BR9813996A (pt) 2-arilbenzo[b]tiofenos úteis para o tratamento de sìndrome da privação de estrogênio
ES2195000T3 (es) Composicion farmaceutica.
ATE246924T1 (de) Neue therapeutische verwendung von nicergoline
ES2150418T3 (es) Composiciones farmaceuticas que comprenden calcitonina.
DE69910608D1 (de) Neue therapeutische verwendung von 1,6-dimethyl-8beta-hydroxymethyl-10alpha-methoxyergolin
ATE305795T1 (de) Verwendung von wachstumshormon und analoga davon für die behandlung von säugern mit familiärer hypercholesterolämie

Legal Events

Date Code Title Description
8364 No opposition during term of opposition